A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

“While GLP-1-based therapies have revolutionized patient care for obesity ... harmful triglycerides and cholesterol while ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...